Cormorant Asset Management, Lp - Net Worth and Insider Trading
Cormorant Asset Management, Lp Net Worth
The estimated net worth of Cormorant Asset Management, Lp is at least $2.3 Billion dollars as of 2024-12-27. Cormorant Asset Management, Lp is the 10% Owner of Ambrx Biopharma Inc and owns about 69,465,823 shares of Ambrx Biopharma Inc (AMAM) stock worth over $674 Million. Cormorant Asset Management, Lp is the of Prometheus Biosciences Inc and owns about 2,223,022 shares of Prometheus Biosciences Inc (RXDX) stock worth over $444 Million. Cormorant Asset Management, Lp is also the 10% Owner of Ambrx Biopharma Inc and owns about 11,231,000 shares of Ambrx Biopharma Inc (AMAM) stock worth over $314 Million. Besides these, Cormorant Asset Management, Lp also holds Turning Point Therapeutics Inc (TPTX) , Axonics Inc (AXNX) , Apellis Pharmaceuticals Inc (APLS) , Avidity Biosciences Inc (RNA) , EyePoint Pharmaceuticals Inc (EYPT) , Bright Minds Biosciences Inc (DRUG) , Kiniksa Pharmaceuticals International PLC (KNSA) , Design Therapeutics Inc (DSGN) , Corbus Pharmaceuticals Holdings Inc (CRBP) , Monte Rosa Therapeutics Inc (GLUE) , Olema Pharmaceuticals inc (OLMA) , Tyra Biosciences Inc (TYRA) , Akouos Inc (AKUS) , Immuneering Corp (IMRX) , Verve Therapeutics Inc (VERV) , Aerovate Therapeutics Inc (AVTE) , Rain Oncology Inc (RAIN) , Ventyx Biosciences Inc (VTYX) , Pyxis Oncology Inc (PYXS) , BioAtla Inc (BCAB) , Kezar Life Sciences Inc (KZR) , Proteostasis Therapeutics Inc (PTI) . Details can be seen in Cormorant Asset Management, Lp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Cormorant Asset Management, Lp has not made any transactions after 2024-11-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Cormorant Asset Management, Lp
Cormorant Asset Management, Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Cormorant Asset Management, Lp owns 36 companies in total, including Akouos Inc (AKUS) , Avidity Biosciences Inc (RNA) , and Turning Point Therapeutics Inc (TPTX) among others .
Click here to see the complete history of Cormorant Asset Management, Lp’s form 4 insider trades.
Insider Ownership Summary of Cormorant Asset Management, Lp
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
AKUS | Akouos Inc | 2020-06-30 | 10 percent owner |
RNA | Avidity Biosciences Inc | 2020-06-16 | 10 percent owner |
TPTX | Turning Point Therapeutics Inc | 2019-04-22 | 10 percent owner |
2018-10-31 | 10 percent owner | ||
2018-07-18 | 10 percent owner | ||
2018-06-25 | 10 percent owner | ||
2018-05-29 | 10 percent owner | ||
2017-12-14 | 10 percent owner | ||
2017-11-13 | 10 percent owner | ||
2016-06-01 | 10 percent owner | ||
2014-08-15 | 10 percent owner | ||
2016-11-03 | 10 percent owner | ||
2020-10-29 | 10 percent owner | ||
2021-03-16 | 10 percent owner | ||
2021-04-27 | 10 percent owner | ||
2020-11-23 | 10 percent owner | ||
2022-12-20 | director | ||
2021-10-13 | 10 percent owner | ||
2021-06-24 | 10 percent owner | ||
2021-07-28 | 10 percent owner | ||
2024-04-01 | 10 percent owner | ||
2021-07-02 | 10 percent owner | ||
2021-03-30 | 10 percent owner | ||
2021-06-28 | 10 percent owner | ||
2020-12-18 | 10 percent owner | ||
2022-01-06 | 10 percent owner | ||
2023-03-30 | 10 percent owner | ||
2021-06-21 | 10 percent owner | ||
2021-10-25 | 10 percent owner | ||
2021-09-17 | 10 percent owner | ||
2016-11-03 | 10 percent owner | ||
2023-09-18 | 10 percent owner | ||
2023-05-29 | other: See below | ||
2023-05-29 | other: See below | ||
2023-10-02 | 10 percent owner | ||
2023-10-23 | 10 percent owner |
Cormorant Asset Management, Lp Latest Holdings Summary
Cormorant Asset Management, Lp currently owns a total of 25 stocks. Among these stocks, Cormorant Asset Management, Lp owns 69,465,823 shares of Ambrx Biopharma Inc (AMAM) as of September 18, 2023, with a value of $674 Million and a weighting of 29.45%. Cormorant Asset Management, Lp owns 2,223,022 shares of Prometheus Biosciences Inc (RXDX) as of March 16, 2021, with a value of $444 Million and a weighting of 19.42%. Cormorant Asset Management, Lp also owns 11,231,000 shares of Ambrx Biopharma Inc (AMAM) as of October 23, 2023, with a value of $314 Million and a weighting of 13.74%. The other 22 stocks Turning Point Therapeutics Inc (TPTX) , Axonics Inc (AXNX) , Apellis Pharmaceuticals Inc (APLS) , Avidity Biosciences Inc (RNA) , EyePoint Pharmaceuticals Inc (EYPT) , Bright Minds Biosciences Inc (DRUG) , Kiniksa Pharmaceuticals International PLC (KNSA) , Design Therapeutics Inc (DSGN) , Corbus Pharmaceuticals Holdings Inc (CRBP) , Monte Rosa Therapeutics Inc (GLUE) , Olema Pharmaceuticals inc (OLMA) , Tyra Biosciences Inc (TYRA) , Akouos Inc (AKUS) , Immuneering Corp (IMRX) , Verve Therapeutics Inc (VERV) , Aerovate Therapeutics Inc (AVTE) , Rain Oncology Inc (RAIN) , Ventyx Biosciences Inc (VTYX) , Pyxis Oncology Inc (PYXS) , BioAtla Inc (BCAB) , Kezar Life Sciences Inc (KZR) , Proteostasis Therapeutics Inc (PTI) have a combined weighting of 37.38% among all his current holdings.
Latest Holdings of Cormorant Asset Management, Lp
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
AMAM | Ambrx Biopharma Inc | 2023-09-18 | 69,465,823 | 9.70 | 673,818,483 |
RXDX | Prometheus Biosciences Inc | 2021-03-16 | 2,223,022 | 199.92 | 444,426,558 |
AMAM | Ambrx Biopharma Inc | 2023-10-23 | 11,231,000 | 28.00 | 314,468,000 |
TPTX | Turning Point Therapeutics Inc | 2019-04-22 | 3,099,099 | 76.01 | 235,562,515 |
AXNX | Axonics Inc | 2018-10-31 | 1,885,826 | 70.98 | 133,855,929 |
APLS | Apellis Pharmaceuticals Inc | 2017-11-13 | 3,473,925 | 32.75 | 113,771,044 |
RNA | Avidity Biosciences Inc | 2020-06-16 | 2,514,545 | 30.00 | 75,436,350 |
EYPT | EyePoint Pharmaceuticals Inc | 2024-05-06 | 8,325,000 | 7.19 | 59,856,750 |
DRUG | Bright Minds Biosciences Inc | 2024-11-04 | 1,059,331 | 39.88 | 42,246,120 |
KNSA | Kiniksa Pharmaceuticals International PLC | 2018-05-29 | 1,731,442 | 20.03 | 34,680,783 |
DSGN | Design Therapeutics Inc | 2021-03-30 | 5,114,844 | 6.25 | 31,967,775 |
CRBP | Corbus Pharmaceuticals Holdings Inc | 2024-09-20 | 2,375,000 | 12.75 | 30,281,250 |
GLUE | Monte Rosa Therapeutics Inc | 2021-06-28 | 3,202,200 | 7.06 | 22,607,532 |
OLMA | Olema Pharmaceuticals inc | 2020-11-23 | 3,270,544 | 6.15 | 20,113,846 |
TYRA | Tyra Biosciences Inc | 2021-09-17 | 1,069,932 | 14.07 | 15,053,943 |
AKUS | Akouos Inc | 2020-06-30 | 789,989 | 13.29 | 10,498,954 |
IMRX | Immuneering Corp | 2024-04-01 | 2,895,273 | 2.33 | 6,745,986 |
VERV | Verve Therapeutics Inc | 2021-06-21 | 984,224 | 6.00 | 5,900,423 |
AVTE | Aerovate Therapeutics Inc | 2021-07-02 | 2,030,691 | 2.67 | 5,421,945 |
RAIN | Rain Oncology Inc | 2021-04-27 | 2,776,657 | 1.21 | 3,359,755 |
VTYX | Ventyx Biosciences Inc | 2021-10-25 | 1,410,303 | 2.38 | 3,356,521 |
PYXS | Pyxis Oncology Inc | 2021-10-13 | 1,118,854 | 1.59 | 1,778,978 |
BCAB | BioAtla Inc | 2020-12-18 | 2,292,060 | 0.64 | 1,462,334 |
KZR | Kezar Life Sciences Inc | 2018-06-25 | 188,840 | 6.64 | 1,253,898 |
PTI | Proteostasis Therapeutics Inc | 2017-12-14 | 165,000 | 1.11 | 183,150 |
Holding Weightings of Cormorant Asset Management, Lp
Cormorant Asset Management, Lp Form 4 Trading Tracker
According to the SEC Form 4 filings, Cormorant Asset Management, Lp has made a total of 4 transactions in Ambrx Biopharma Inc (AMAM) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Ambrx Biopharma Inc is the acquisition of 2,152,738 shares on September 18, 2023, which cost Cormorant Asset Management, Lp around $20 Million.
According to the SEC Form 4 filings, Cormorant Asset Management, Lp has made a total of 1 transactions in Prometheus Biosciences Inc (RXDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prometheus Biosciences Inc is the acquisition of 375,000 shares on March 16, 2021, which cost Cormorant Asset Management, Lp around $7 Million.
According to the SEC Form 4 filings, Cormorant Asset Management, Lp has made a total of 1 transactions in Ambrx Biopharma Inc (AMAM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Ambrx Biopharma Inc is the acquisition of 1,307,311 shares on October 23, 2023, which cost Cormorant Asset Management, Lp around $9 Million.
More details on Cormorant Asset Management, Lp's insider transactions can be found in the Insider Trading History of Cormorant Asset Management, Lp table.Insider Trading History of Cormorant Asset Management, Lp
- 1
Cormorant Asset Management, Lp Trading Performance
GuruFocus tracks the stock performance after each of Cormorant Asset Management, Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Cormorant Asset Management, Lp is 21.27%. GuruFocus also compares Cormorant Asset Management, Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Cormorant Asset Management, Lp within 3 months outperforms 26 times out of 37 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Cormorant Asset Management, Lp's insider trading performs compared to the benchmark.
Performance of Cormorant Asset Management, Lp
Cormorant Asset Management, Lp Ownership Network
Cormorant Asset Management, Lp Owned Company Details
What does Akouos Inc do?
Who are the key executives at Akouos Inc?
Cormorant Asset Management, Lp is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .
Akouos Inc (AKUS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akouos Inc Insider Transactions
Cormorant Asset Management, Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Cormorant Asset Management, Lp. You might contact Cormorant Asset Management, Lp via mailing address: 200 Clarendon Street, 52nd Floor, Boston Ma 02116.